Congratulations Dr. Lasky!

We’re proud to announce some news about Dr. Lasky!  He has been promoted to director of our Bleeding and Clotting Disorders Clinic.

As one of our board-certified Pediatric Hematology-Oncology physicians, he will continue to see patients affected by childhood cancer. But he will also oversee all aspects of medical treatment for our patients affected by bleeding and clotting disorders, such as hemophilia and von Willebrand disease and other related conditions.

Since 2009, Dr. Lasky has served as principal investigator for a number of clinical trials and has participated in other research activities aimed at improving treatments for those with bleeding and clotting issues.

Congratulations Dr. Lasky!

CSL627_3001 Hemophilia A

Bleeding and Clotting Disorders

Protocol:CSL627_3001

Condition or Disease: Hemophilia A

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII SingleChain, CSL627) in Subjects with Severe Hemophilia A

Principal I investigator: Joseph Lasky III, MD

ALN-AT3SC-003 Hemophilia A or B

Bleeding and Clotting Disorders

Protocol:ALN-AT3SC-003

Condition or Disease: Hemophilia A or B

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients with Hemophilia A or B, with Inhibitory Antibodies to Factor VIII or IX

Principal I investigator: Joseph Lasky III, MD

More Info: //clinicaltrials.gov/ct2/show/NCT03417102

ALN-AT3SC-004 Hemophilia A or B

Bleeding and Clotting Disorders

Protocol:ALN-AT3SC-004

Condition or Disease: Hemophilia A or B

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: ATLAS-A/B: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, Without Inhibitory Antibodies to Factor VIII or IX

Principal I investigator: Joseph Lasky III, MD

More Info: //clinicaltrials.gov/ct2/show/NCT03417245

1160.106 Venous thrombosis

Bleeding and Clotting Disorders

Protocol:1160.106

Condition or Disease: Venous thrombosis

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Open-label, randomized, parallel-group, active-controlled, multi-centre, non-inferiority study of dabigatran etexilate versus standard of care for venous thromboembolism treatment in children from birth to less than 18 years of age: The DIVERSITY study

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT01895777

1160.108 Venous Thromboembolism, Secondary Prevention

Bleeding and Clotting Disorders

Protocol:1160.108

Condition or Disease: Venous Thromboembolism, Secondary Prevention

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Open label, single arm safety prospective cohort study of dabigatran etexilate for secondary prevention of venous thromboembolism in children from 0 to less than 18 years

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT02197416

1321.7 Hemorrhage

Bleeding and Clotting Disorders

Protocol:1321.7

Condition or Disease: Hemorrhage

Study Type: Interventional (Clinical Trial)

Status: Open for enrollment

Study Title: Single dose, open label, uncontrolled, safety trial of intravenous administration of idarucizumab to paediatric patients enrolled from ongoing phase IIb/III clinical trials with dabigatran etexilate for the treatment and secondary prevention of venous thromboembolism.

Principal I investigator: Alan Ikeda, MD

More Info: //clinicaltrials.gov/ct2/show/NCT02815670

GENA-99 Hemophilia A

Bleeding and Clotting Disorders

Protocol:GENA-99

Condition or Disease: Hemophilia A

Study Type: Observational

Status: Open for enrollment

Study Title: Prospective, multinational, non-interventional post-authorisation study to document the long-term immunogenicity, safety, and efficacy of Human-cl rhFVIII (simoctocog alfa) in patients with haemophilia A treated in routine clinical practice

Principal I investigator: Joseph Lasky III, MD

More Info: //clinicaltrials.gov/ct2/show/NCT02962765

NN7415-4322 Hemophilia A or B

Bleeding and Clotting Disorders

Protocol:NN7415-4322

Condition or Disease: Hemophilia A or B

Study Type: Observational

Status: Open for enrollment

Study Title: A prospective, multi-national, non-interventional study in haemophilia A and B patients with or without inhibitors treated according to routine clinical treatment practice (explorerâ„¢6) 

Principal I investigator: Joseph Lasky III, MD

More Info: //www.clinicaltrials.gov/ct2/show/NCT03741881